Paper detail

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data

Phase I oncology trials aim to identify a safe dose - often the maximum tolerated dose (MTD) - for subsequent studies. Conventional designs focus on population-level toxicity modeling, with recent attention on leveraging pharmacokinetic (PK) data to improve dose selection. We propose the Precision Dose-Finding (PDF) design, a novel Bayesian phase I framework that integrates individual patient PK profiles into the dose-finding process. By incorporating patient-specific PK parameters (such as volume of distribution and elimination rate), PDF models toxicity risk at the individual level, in contrast to traditional methods that ignore inter-patient variability. The trial is structured in two stages: an initial training stage to update model parameters using cohort-based dose escalation, and a subsequent test stage in which doses for new patients are chosen based on each patient's own PK-predicted toxicity probability. This two-stage approach enables truly personalized dose assignment while maintaining rigorous safety oversight. Extensive simulation studies demonstrate the feasibility of PDF and suggest that it provides improved safety and dosing precision relative to the continual reassessment method (CRM). The PDF design thus offers a refined dose-finding strategy that tailors the MTD to individual patients, aligning phase I trials with the ideals of precision medicine.